Expression of TM4SF1 is high across a number of tumor types, and its inverse correlation with PVRL4 (NECTIN4) expression in TCGA-BLCA and CCLE (Supplementary Figs. 11D and 12) suggests that TM4SF1-directed therapies might be complementary to enfortumab vedotin (EV) therapy, an antibody-drug conjugate that targets NECTIN4 that was recently approved for frontline treatment of patients with locally-advanced/metastatic urothelial cancers45,46. Here, NECTIN4 is linked to neoplasm.